Document is current

Article History

Received: 24 February 2022

Accepted: 20 June 2022

First Online: 12 July 2022

Declarations

:

: Dr. Kenmotsu reported of grants and personal fees from Chugai Pharmaceutical Co., Ltd., during the conduct of the study; personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from Nippon Boeringer Ingelheim Co., Ltd, personal fees from Eli Lilly Japan K.K., personal fees from Kyowa Kirin Co., Ltd., personal fees from Bristol-Myers Squibb K.K., personal fees from MSD K.K., grants and personal fees from Novartis Pharma K.K., personal fees from Daiichi Sankyo Co., Ltd., grants and personal fees from AstraZeneca K.K., personal fees from Pfizer Japan Inc., and personal fees from Taiho Pharmaceutical Co., Ltd., outside the submitted work. Dr. Imamura reported personal fees from Chugai Pharmaceutical Co., Ltd. and grants from Otsuka Pharmaceutical Co., Ltd. outside the submitted work. Dr. Kawamura reported personal fees from AstraZeneca K.K. outside the submitted work. Dr. Omori reported personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Novartis Pharma K.K., personal fees from MSD K.K., and personal fees from AstraZeneca K.K. outside the submitted work. Dr. Nakashima reported personal fees from Taiho Phamaceutical Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from AstraZeneca K.K., personal fees from Nippon Boehringer Ingelheim Co., Ltd., and personal fees from Nippon Kayaku Co., Ltd. outside the submitted work. Dr. Wakuda reported grants and personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., personal fees from Eli Lilly Japan K.K., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from MSD K.K., grants and personal fees from AstrazZeneca K.K., grants from Novartis Pharma K.K., and grants from AbbVie GK outside the submitted work. Dr. Ono reported personal fees from AstraZeneca K.K., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., and personal fees from Novartis Pharma K.K. outside the submitted work. Dr. Taira reported personal fees from Kyowa Kirin Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Eli Lilly Japan K.K., personal fees from Taiho Pharmaceutical Co., Ltd., and personal fees from Daiichi Sankyo Co., Ltd. outside the submitted work. Dr. Naito reported personal fees from Ono Pharmaceutical Co., Ltd. outside the submitted work. Dr. Murakami reported grants and personal fees from AstraZeneca K.K., Pfizer Japan Inc., personal fees from Eli Lilly Japan K.K., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants from AbbVie GK, grants and personal fees from Daiichi Sankyo Co., Ltd., grants from IQVIA Japan K.K., personal fees from Bristol-Myers Squibb K.K., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from MSD K.K., personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Nippon Boehringer Ingelheim Co., Ltd., and personal fees from Novartis Pharma K.K. outside the submitted work. Dr. Yamamoto reported grants and personal fees from MSD K.K., grants and personal fees from AstraZeneca K.K., grants and personal fees from Ono Pharmaceutocal Co., Ltd., personal fees from Thermo Fisher Scientific K.K., grants and personal fees from Daiichi Sankyo Co., Ltd., grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Nippon Boehringer-Ingelheim Co., Ltd., grants and personal fees from Novartis Pharma K.K., grants and personal fees from Pfizer Japan Inc., personal fees from Bristol-Myers Squibb K.K., personal fees from Life Technologies Japan Ltd., personal fees from Nippon Kayaku Co., Ltd., personal fees from Merck Biopharma Co., Ltd., grants from Astellas Pharma Inc., grants from Tsumura & Co., grants from Shionogi & Co., Ltd., grants from AbbVie GK., grants from Amgen Inc., grants from Kyorin Pharmaceutical Co., Ltd., grants from Eisai Co., Ltd., grants from Terumo Medical Co., grants from Toppan IncInc., and grants from Tosoh Co. outside the submitted work. Dr. Takahashi reported grants and personal fees from AstraZeneca K.K., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from MSD K.K., grants and personal fees from Pfizer Japan Inc., personal fees from Nippon Boehringer Ingelheim Co. Ltd., and personal fees from Roche Diagnostics K.K. outside the submitted work. Dr. Tanigawara reported personal fees from Chugai Pharmaceutical Co., Ltd., grants from Millennium Pharmaceuticals Inc., and grants from Taiho Pharmaceutical Co. Ltd. outside the submitted work. All remaining authors have declared no conflicts of interest.